

Arrowhead Pharmaceuticals, Inc. Investor Relations Department 225 South Lake Avenue Suite 1050 Pasadena, CA 91101 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ARWR	
Last Trade:	1.60
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.20 - 8.22
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAibased therapeutics leverage this natural pathway of gene silencing.

... (more)

## **Stock Performance**



## Press Releases [View all]

Jun 9, 2017

Arrowhead Pharmaceuticals Reports
Inducement Grants under NASDAQ
Marketplace Rule 5635(c)(4)

May 3, 2017

Arrowhead Reports Fiscal 2017 Second Quarter Results

Apr 26, 2017

<u>Arrowhead Pharmaceuticals to Webcast</u> <u>Fiscal 2017 Second Quarter Results</u>

Apr 24, 2017

 $\frac{\text{Arrowhead Pharmaceuticals Presents ARC-}}{\text{AAT Clinical Data at The International Liver}}\\ \frac{\text{Congress}^{\text{TM}}}{\text{Congress}^{\text{TM}}}$ 

Apr 20, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™

## Financials [View all]

Second Quarter Financial Results

Dec 14, 2016

Annual Report (10-K)

Feb 1, 2017

Proxy Statement (DEF 14A)

May 3, 2017

Quarterly Report (10-Q)

Feb 6, 2017

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)